Home / Health / Immunization of Ad26.COV2.S vaccine against human SARS-CoV-2 strains.

Immunization of Ad26.COV2.S vaccine against human SARS-CoV-2 strains.



Ad26.COV2.S vaccine1–3 It has shown clinical efficacy against symptomatic COVID-19, including against the partially neutralizing antibody-resistant variant B.1.351.1However, the immunization potential of this vaccine in humans against the strains of concern SARS-CoV-2 remains unclear. We reported the immune and cellular level immune responses from 20 subjects vaccinated with Ad26.COV2.S from the COV1001 Phase 1/2 clinical trial.2 Compared to the original SARS-CoV-2 strain WA1/2020 as well as the concerning strains B.1.1.7, CAL.20C, P.1. and B.1.351, Ad26.COV2.S induced values. The median pseudovirus was neutral in assays for 5.0 and 3.3-fold decreased antibody levels compared to the B.1.351 and P.1 variants, respectively, compared to WA1

/2020 on Day 71 after vaccination. The median antibody binding antibody was 2.9 and 2.7 times lower than variant B.1.351 and P.1, respectively, compared to WA1/2020. Antibody-dependent cell phagocytosis, complement accumulation. posts And most NK cell activation responses were treated against B.1.351 variant. CD8 and CD4 T cell responses, including central memory responses and effects. Comparisons were made between variants WA1/2020, B.1.1.7, B.1.351, P.1 and CAL.20C. These data demonstrated the neutralization of the antibody response induced by Ad26.COV2. .S was decreased compared to variants B.1.351 and P.1, but functional non-neutral antibody responses and T cell responses were largely maintained compared to SARS- variants. CoV-2. These findings have implications for the prevention of the SARS-CoV-2 vaccine. worrisome


Source link